Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Rises By 31.9%

Immix Biopharma, Inc. (NASDAQ:IMMX) was the recipient of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 2,990,326 shares, a growth of 31.9% from the January 15th total of 2,266,456 shares. Currently, 12.7% of the company’s shares are sold short. Based on an average daily volume of 961,464 shares, the days-to-cover ratio is presently 3.1 days. Based on an average daily volume of 961,464 shares, the days-to-cover ratio is presently 3.1 days. Currently, 12.7% of the company’s shares are sold short.

Institutional Trading of Immix Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Allworth Financial LP acquired a new stake in Immix Biopharma in the 4th quarter valued at $30,000. Velan Capital Investment Management LP purchased a new stake in shares of Immix Biopharma in the second quarter worth about $52,000. Mathes Company Inc. acquired a new stake in shares of Immix Biopharma in the fourth quarter valued at about $56,000. Tocqueville Asset Management L.P. raised its holdings in shares of Immix Biopharma by 37.4% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock valued at $84,000 after buying an additional 10,950 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in Immix Biopharma during the 4th quarter worth approximately $112,000. 11.26% of the stock is owned by hedge funds and other institutional investors.

Immix Biopharma Price Performance

IMMX stock traded up $0.79 during midday trading on Tuesday, reaching $8.12. 881,763 shares of the company’s stock traded hands, compared to its average volume of 986,389. Immix Biopharma has a fifty-two week low of $1.34 and a fifty-two week high of $8.25. The business has a 50-day moving average price of $5.77 and a two-hundred day moving average price of $3.91. The company has a market capitalization of $429.99 million, a P/E ratio of -10.55 and a beta of 0.31.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Wall Street Zen cut Immix Biopharma from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Finally, Mizuho started coverage on shares of Immix Biopharma in a report on Monday, February 9th. They issued an “outperform” rating and a $14.00 target price for the company. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Immix Biopharma has an average rating of “Hold” and a consensus target price of $11.00.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.